Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

ELIQUIS 5 MG TABLET

apixaban
$5.5265per EA

Strength

5 mg/1

Manufacturer

E.R. Squibb & Sons, L.L.C.

NDC

00003089431

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

1/1/2026

Active Ingredients

APIXABAN

Approval Type

New Drug (NDA)

FDA Application

NDA202155

On Market Since

12/28/2012

Pharmacological Classes

Factor Xa Inhibitor
Factor Xa Inhibitors

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

-43.0%

1Y

-43.0%

3Y

-38.4%

5Y

-30.8%

All

+28.2%

Generic Alternatives

1 alternative • Same active ingredient

ELIQUIS 5 MG TABLET
Brand
00003089421•E.R. Squibb & Sons, L.L.C.
$5.5265

Related Drugs

Same classification

XARELTO 1 MG/ML SUSPENSION
Brand
50458057501•Janssen Pharmaceuticals Inc.
$3.7634
per ML
XARELTO 2.5 MG TABLET
Brand
50458057710•Janssen Pharmaceuticals Inc.
$9.7866
per EA
XARELTO 2.5 MG TABLET
Brand
50458057718•Janssen Pharmaceuticals Inc.
$9.7866
per EA
XARELTO 2.5 MG TABLET
Brand
50458057760•Janssen Pharmaceuticals Inc.
$9.7866
per EA
SAVAYSA 60 MG TABLET
Brand
65597020305•Daiichi Sankyo Inc.
$12.4609
per EA
SAVAYSA 60 MG TABLET
Brand
65597020390•Daiichi Sankyo Inc.
$12.4609
per EA
SAVAYSA 30 MG TABLET
Brand
65597020205•Daiichi Sankyo Inc.
$12.4819
per EA
SAVAYSA 30 MG TABLET
Brand
65597020290•Daiichi Sankyo Inc.
$12.4819
per EA
SAVAYSA 30 MG TABLET
Brand
65597020230•Daiichi Sankyo Inc.
$14.5678
per EA
SAVAYSA 60 MG TABLET
Brand
65597020330•Daiichi Sankyo Inc.
$14.6324
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy